San Diego, CA, USA – January 12, 2015–HUYA Bioscience International (HUYA) announced today that Shenzhen Chipscreen Biosciences (Chipscreen) has obtained marketing approval from the Chinese FDA for the world’s first oral HDAC inhibitor, chidamide, for the treatment of relapsed or...
Chidamide
While hydroxamates, vorinostat and belinostat, and cyclic peptide romidepsin have been approved by FDA for T-cell lymphoma treatment [4, 5, 17], chidamide represents a novel oral benzamide class HDAC inhibitor with significant single-agent activity and manageable toxicity in relapsed or refractory ...
"We are pleased to confirm that the trial has achieved its primary endpoint although the pathological subtypes of PTCL in Chinese population are significantly different from that in North America and Europe, where two FDA approved PTCL drugs, Pralatrexate and Romidepsin, were tested," stated Xian-...